The Total Artificial Heart as a Bridge to Transplantation

Copeland, Jack G.; Levinson, M.; Smith, Richard G.; Icenogle, Timothy B.; Vaughn, Cecil C.; Cheng, Kevin; Ott, Richard A.; Emery, Robert W.

doi:10.1001/jama.1986.03380210087031

Cited by 83 publications

(11 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Clark survived for a total of 112 days with the full support of the TAH [10,14,15]. The first TAH implanted as a BTT was performed in 1985 by Copeland and colleagues at the University of Arizona (AZ, USA) [10,16]. Improvements in immunosuppression and the subsequent increase in cardiac transplantation in the early 1980s paved the way for mechanical circulatory-support devices as a BTT.…”

Section: History and Evolution Of Ventricular Assist Device Therapymentioning

confidence: 99%

HeartMate^®II continuous-flow left ventricular assist system

Sheikh

Russell

2011

Expert Review of Medical Devices

View full text Add to dashboard Cite

Left ventricular assist devices (LVADs) have emerged as a beneficial therapeutic strategy proven to improve the morbidity and mortality of patients with advanced heart failure. Continuous-flow rotary LVADs have been developed in the hopes of delivering circulatory support in a more durable manner with fewer device-related complications. The HeartMate(®) II continuous-flow left ventricular assist system (LVAS; Thoratec Corporation, Pleasanton, CA, USA) has become the standard of care for heart failure patients who require long-term mechanical circulatory support. The efficacy of the HeartMate II has been demonstrated in patients where temporary support with an LVAD is needed until a suitable donor organ can be found for transplant (termed 'bridge to transplantation'), as well as for terminally-ill heart failure patients who are not candidates for transplant ('destination therapy'). When directly compared with a pulsatile LVAD, the implantation of a HeartMate II LVAS resulted in an overall improvement in survival with a reduction in the number of device-related complications and adverse events. The purpose of this article is threefold: to describe the history of the development of continuous-flow LVADs; to describe the technology of the HeartMate II; and, finally, to review the clinical outcomes in patients who have been implanted with the device.

show abstract

Section: History and Evolution Of Ventricular Assist Device Therapymentioning

confidence: 99%

HeartMate^®II continuous-flow left ventricular assist system

Sheikh

Russell

2011

Expert Review of Medical Devices

View full text Add to dashboard Cite

show abstract

“…Until recently, only pneumatic TAHs with extracorporeal driving systems have been clinically used, the most prominent examples being the JARVIK 7 TM and its successor, the CARDIOWEST TM . They have been used as a bridge to transplant or, in a few cases, as permanent replacement systems (Copeland et al 1989). A novel electrohydraulic TAH, the Abiomed ABIOCOR TM is currently being tested in clinical studies.…”

Section: Clinical Use and Indicationsmentioning

confidence: 99%

Mechanical Blood Pumps for Cardiac Assistance

Akdis

Reul

2005

Applied Bionics and Biomechanics

View full text Add to dashboard Cite

Cardiac assist devices are classified into the traditional engineering categories of displacement and rotary pumps. Clinical use and indications of the various pump categories are outlined and a detailed description of currently available systems is given. The first part deals with extracorporeal as well as implantable ventricular assist devices (VAD) of the displacement type and is followed by a section on current developments in the field of total artificial hearts (TAH). The second part covers the rotary pump category from cardiopulmonary bypass applications to implantable systems, including specific design aspects of radial, diagonal, and axial pumps.

show abstract

“…In a review of 56 patients who were bridged to transplantation, 16% developed signs of cerebral embolism (18). Considering the fact that all long-term TAH recipients (227 -622 days on TAH) developed strokes, the risk of thromboembolism increases synchronously with the bridging duration.…”

Section: Thrombus Formation and Thromboembolismmentioning

confidence: 99%